We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$60.9M
Cap. Flow
+$27.1M
Cap. Flow %
5.19%
Top 10 Hldgs %
45.15%
Holding
120
New
43
Increased
21
Reduced
16
Closed
38

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$22.2M
2
BHVN icon
Biohaven
BHVN
+$17.4M
3
MBX
MBX Biosciences
MBX
+$14.3M
4
CGON icon
CG Oncology
CGON
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.9M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$28.9M
2
ACLX
Arcellx
ACLX
+$21.7M
3
TWST icon
Twist Bioscience
TWST
+$21.3M
4
TERN
Terns Pharmaceuticals
TERN
+$17.6M
5
ROIV icon
Roivant Sciences
ROIV
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Financials 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.33B
$50.9M 9.75%
1,035,496
+148,603
+17% +$6.66M
ABVX
2
Abivax
ABVX
$11.9B
$34.9M 6.69%
313,791
-77,992
-20% -$9.23M
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$2.02B
$28.4M 5.44%
1,215,743
-123,636
-9% -$2.69M
RVMD icon
4
Revolution Medicines
RVMD
$39.6B
$27.4M 5.24%
281,632
+219,600
+354% +$22.2M
IMVT icon
5
Immunovant
IMVT
$8.27B
$18.5M 3.55%
746,494
+101,535
+16% +$2.63M
PRAX icon
6
Praxis Precision Medicines
PRAX
$8.77B
$18.1M 3.47%
56,267
+35,200
+167% +$10.9M
MBX
7
MBX Biosciences
MBX
$2.99B
$14.9M 2.85%
499,469
+420,916
+536% +$14.3M
MLYS icon
8
Mineralys Therapeutics
MLYS
$2.39B
$14.4M 2.77%
533,378
+243,329
+84% +$7.14M
ELVN icon
9
Enliven Therapeutics
ELVN
$3.8B
$14.2M 2.73%
+363,438
New +$10.1M
CGON icon
10
CG Oncology
CGON
$6.34B
$13.9M 2.66%
+205,622
New +$11.7M
BHVN icon
11
Biohaven
BHVN
$2.32B
$13.5M 2.58%
+1,594,491
New +$17.4M
SRZN icon
12
Surrozen
SRZN
$255M
$13.5M 2.58%
525,639
-94,127
-15% -$2.26M
ROIV icon
13
Roivant Sciences
ROIV
$24.8B
$10.7M 2.05%
385,800
-580,898
-60% -$14.9M
EYPT icon
14
EyePoint Inc
EYPT
$1.12B
$10.5M 2%
810,764
+456,915
+129% +$6.83M
ARQT icon
15
Arcutis Biotherapeutics
ARQT
$3.56B
$9.75M 1.87%
413,792
+189,052
+84% +$4.82M
GPCR icon
16
Structure Therapeutics
GPCR
$3.45B
$9.65M 1.85%
200,267
-150,806
-43% -$10.3M
AMLX icon
17
Amylyx Pharmaceuticals
AMLX
$1.97B
$9.31M 1.78%
669,685
+104,545
+18% +$1.47M
DYN icon
18
Dyne Therapeutics
DYN
$3.92B
$9.18M 1.76%
506,075
-329,125
-39% -$5.68M
EWTX icon
19
Edgewise Therapeutics
EWTX
$4.28B
$9.16M 1.75%
290,864
-70,012
-19% -$2.02M
CYTK icon
20
Cytokinetics
CYTK
$10.9B
$8.54M 1.64%
129,577
-17,401
-12% -$1.11M
SYRE icon
21
Spyre Therapeutics
SYRE
$8.7B
$8.45M 1.62%
167,606
+135,229
+418% +$5.1M
DNLI icon
22
Denali Therapeutics
DNLI
$3.7B
$8.19M 1.57%
426,561
+7,503
+2% +$149K
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.6B
$8.18M 1.57%
140,755
-207,850
-60% -$9.58M
CLDX icon
24
Celldex Therapeutics
CLDX
$2.77B
$8.07M 1.54%
+254,267
New +$6.93M
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.06B
$7.65M 1.46%
72,577
+13,147
+22% +$1.16M
1
2 3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Stempoint Capital held 120 positions worth $522M, down 10% from $583M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Stempoint Capital deployed $27.1M of net new capital in Q1 2026, opening 43 new positions and adding to 21 existing holdings. Its largest new stake was Biohaven: 1,594,491 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $21.3M trimmed.

  • Stempoint Capital's largest Q1 2026 buy was Biohaven: 1,594,491 shares worth $13.5M.
  • Stempoint Capital added most to Revolution Medicines in Q1 2026, an estimated $22.2M increase.
  • Stempoint Capital's biggest Q1 2026 reduction was Twist Bioscience, cutting an estimated $21.3M.
  • Stempoint Capital fully exited Centessa Pharmaceuticals in Q1 2026, selling an estimated $28.9M.
  • Stempoint Capital's ten largest holdings make up 45% of its $522M portfolio in Q1 2026.
  • Stempoint Capital opened 43 new positions and closed 38 in Q1 2026.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $522M.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.